A recent study uncovers how drug-resistant cancer cells induce changes in the tumor microenvironment. This phenomenon promotes cancer recurrence and explains why initially effective targeted therapies ...

Functional genomics can help deconvolute the link between genotype and phenotype in disease, revealing new drug targets and ...

Research suggests a new drug slowed the growth of prostate cancer cells, including those with a resistance to the hormone therapy enzalutamide.

The recurrence of breast cancer, often driven by drug resistance, remains a formidable challenge in oncology. Despite significant advancements in targeted ...

Prostate cancer that has become resistant to hormone therapy could be treated using a new drug that is currently in clinical trials for ovarian and bile duct cancer, according to research published in ...

According to the World Health Organization (WHO), multidrug-resistant pathogens caused over 1.27 million deaths worldwide in ...

Despite significant therapeutic advances, breast cancer remains a leading cause of cancer-related death in women. Treatment ...

JERUSALEM, Jan. 12 (Xinhua) -- A new study has found that a combination of two existing biological drugs for multiple myeloma cancer can halt the progression of the disease, Israel's Tel Aviv Sourasky ...

Wockhardt’s experimental drug, Zaynich, has shown impressive results, achieving a 100% cure rate in clinical trials for ...

Dual blocking SHP2 and FGFR2 can not only promote the targeted tumor-killing effects and overcome FGFR2 inhibitor resistance caused by feedback activation, but also activate T cell-mediated anti-tumor ...